Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, oncology, immunology, neuroscience, and other therapeutic areas worldwide.

The markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market ...

Investing.com - U.S. stock futures climb on Thursday as traders gauge a stream of corporate earnings and fresh U.S. economic data. Amazon (NASDAQ:AMZN) is set to report its quarterly results, with ...

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Americans fear faster inflation is on the horizon. The University of Michigan’s latest consumer survey, released Friday, showed that Americans’ inflation expectations for the year ahead surged ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024 Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before tomorrow’s bell. Given recent price action ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...